Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$1.06 USD

1.06
5,378,168

-0.06 (-5.36%)

Updated Aug 6, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks News

Zacks Equity Research

Is a Beat in Store for Amarin (AMRN) This Earnings Season?

Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

Zacks Equity Research

What's in Store for Innoviva (INVA) This Earnings Season?

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the first quarter.

Zacks Equity Research

Allogene's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.

Zacks Equity Research

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

Is (ALLO) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why Momentum Investors Will Love Allogene Therapeutics (ALLO)

Does Allogene Therapeutics (ALLO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Perrigo (PRGO) Stock Rises on Stellar Q1 Preliminary Results

Perrigo (PRGO) announces better-than-expected preliminary results for first-quarter 2020. Shares gain.

Zacks Equity Research

Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?

Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock

Allogene Therapeutics (ALLO) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

Will Allogene Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Allogene Therapeutics.